With the Novel Coronavirus (COVID-19) pandemic event, hospitals are working to provide proper isolation procedures for the regularly admitted patient and their medical teams, while in parallel, supporting the COVID-19 infected population. Unfortunately, during these global events, fundamental process of care measures like documentation of vital signs, including proper monitoring of a patient’s urine output, can be difficult. Urine output is a key metric in monitoring the fluid state of a patient, especially in COVID-19 patients that suffer from pneumonia, which can jeopardize their kidney functionality. Acute Kidney Injury (AKI) happens to be a severe symptom of COVID-19, especially for patients in a critical condition.
Some hospitals have adopted a unique approach to monitoring a patient’s urine flow, one that eliminates this near-proximity, manual and time-consuming process. With electronic, urine-monitoring systems like the Clarity RMS® from RenalSense, a technology that continuously measures urine flow, automatically transmitting to the medical staff real-time data, and notifications of fluctuations, on a 24/7 basis, the hospital staff has peace of mind knowing the patients urine flow is being captured on the hour and tracked electronically. This information, which reflects changes in renal function, provides an early sign of AKI risk and facilitates rapid intervention.
Dr. Hassan Khouli, Chairman of the Department of Critical Care Medicine at The Cleveland Clinic, says that when it comes to surveillance, the CDC states, “when transmission of epidemiologically-important organisms continues despite implementation and documented adherence to infection prevention and control strategies, obtain consultation from persons knowledgeable in infection control and healthcare epidemiology to review the situation and recommend additional measures for control”.
Once the patient is connected, the hospital staff can monitor urine output of a patient at a distance – a very useful tool for the isolation room. The technology limits the number of times that staff needs to go into an isolation room that maintains an infected patient and allows them to visually view the graphically trended urine output remotely – this alerts them automatically that a patient’s urine output has dropped below globally accepted standards.
Avi Kleiman, CEO and founder, RenalSense, states, “We are all living through challenging times with the Corona Virus. However, we have found that RenalSense products are contributing to the fight against the virus. Our customers have shared with us how the Clarity RMS not only provides valuable information, but also help combat contamination. We are seeing an increase in orders, despite the limitations of physical presence at the hospitals. To address this reality we are performing training and support virtually with standard products. May our efforts provide helps reduce the pain and cost of this monstrous challenge.”
RenalSense is a Jerusalem-based privately owned medical device company dedicated to real-time renal diagnostics. The company’s first product, Clarity RMS®, provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics. RenalSense‘s next generation products will provide additional real-time parameters and expanded diagnostic capabilities, to further improve critical care management in the ICU and peri-operative setting.
For more information, contact Jean-Paul Benhamou, VP, Sales & Marketing- Global:
jpbenhamou at renalsense.com
Source: PR Newswire